Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06644742 · ClinicalTrials.gov registry record

PKP2-ACM Natural History Study

A clinical trial of Cardiovascular Diseases and Heart Diseases, sponsored by Rocket Pharmaceuticals.

Recruiting
Registry status
36
Enrollment target
3
Study locations

NCT06644742: Recruiting study of Cardiovascular Diseases and Heart Diseases, sponsored by Rocket Pharmaceuticals.

NCT06644742 is a study of Cardiovascular Diseases and Heart Diseases that is actively recruiting participants, run by Rocket Pharmaceuticals. The registered enrollment target is 36 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06644742, a study of Cardiovascular Diseases and Heart Diseases, is actively recruiting participants, sponsored by Rocket Pharmaceuticals.

RECRUITING
Registry status
36 participants
Enrollment target
3
Study locations

Study Summary

The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.

Primary Outcome

Evaluate electrophysiology as assessed by heart rate and rhythm

Study Locations (3)

Massachusetts

  • Boston Children's Hospital - Boston

North Carolina

  • Duke University - Durham

Other

  • Amsterdam UMC - Amsterdam

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2026-03
Est. Completion 2031-04
Rocket Pharmaceuticals

10 total trials

What NCT06644742 shows while recruiting

NCT06644742 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).

The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT06644742 reports a single indexed study location in Massachusetts, North Carolina, Other.

Frequently Asked Questions

What is clinical trial NCT06644742 about?

NCT06644742 is a clinical study titled "PKP2-ACM Natural History Study". The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.

What is the current status of trial NCT06644742?

This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2026-03. Estimated completion is 2031-04.

What conditions does trial NCT06644742 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Cardiomyopathies, Genetic Diseases.

Who is sponsoring clinical trial NCT06644742?

This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06644742 being conducted?

This trial has 3 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06644742's enrollment target sits among peer trials

36 255th of 300 higher than 45 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT06644742, the US trial registry maintained by the National Library of Medicine. NCT06644742 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.